Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | GYS1 | P13807 | 4/20 | 0.34 |
| ▸ | MAOB | P27338 | 7/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13586502 | 0.94 | F10 (0.36) | BRD4MAOBF10MAOANR1H4 | |
| SCHEMBL13586573 | 0.87 | GYS1 (0.33) | GYS1MAOBFFAR4NR1H4 | |
| SCHEMBL13586380 | 0.86 | BRD4 (0.38) | BRD4 | |
| SCHEMBL12716882 | 0.85 | NAAA (0.33) | BRD4FFAR4F10PTPN1 | |
| SCHEMBL12823839 | 0.84 | NR1H4 (0.35) | BRD4GYS1FFAR4F10NR1H4 | |
| SCHEMBL12822614 | 0.84 | MAOB (0.39) | BRD4MAOBFFAR4MAOA | |
| SCHEMBL12823844 | 0.84 | FFAR4 (0.33) | GYS1FFAR4 | |
| SCHEMBL12823373 | 0.84 | FFAR4 (0.33) | GYS1FFAR4 | |
| SCHEMBL12823849 | 0.84 | FFAR1 (0.36) | BRD4GYS1MAOBFFAR4F10 | |
| SCHEMBL13654179 | 0.83 | GYS1 (0.37) | GYS1MAOBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | BRD4 1478/4885GYS1 4252/4885MAOB 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.